Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Bright White Light May Offset Negative Effects of ADT in Older Men With Prostate Cancer

June 20th 2021

Tanya Dorff, MD, discusses encouraging data from a study evaluating bright white light in older patients with prostate cancer and updates from the phase ARAMIS trial.

177Lu-PSMA-617 Receives FDA Breakthrough Therapy Designation for mCRPC

June 17th 2021

The FDA granted a breakthrough therapy designation to 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Juárez Soto on the Rationale for Apalutamide Plus ADT in mCSPC

June 17th 2021

Álvaro Juárez Soto, MD, discusses the rationale for examining apalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, as seen in the phase 3 TITAN study.

Dr. Choudhury on Emerging Treatment Strategies in mCRPC

June 15th 2021

Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.

Dr. Pieczonka on the Design of the Phase 3 VERACITY Trial With VERU-111 in mCRPC

June 15th 2021

Christopher Pieczonka, MD, discusses the design of the phase 3 VERACITY trial studying VERU-111 in patients with metastatic castration-resistant prostate cancer.

Water Vapor Ablation Therapy Shows Encouraging Efficacy, Safety in Prostate Cancer

June 14th 2021

A water vapor ablation therapy has been shown to be able to reach and treat all prostate regions and eradicate intermediate risk, grade group 2 prostate cancer with acceptable safety and tolerability.

Addition of Abiraterone to ADT plus Docetaxel Yields Improvement in rPFS in De Novo mCSPC

June 9th 2021

Adding abiraterone acetate and prednisone to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival in patients with de novo metastatic castration-sensitive prostate cancer.

Latest in Myeloma, Prostate Cancer, and Lymphoma From ASCO 2021: Drs Neal Shore, Loretta Nastoupil, and Sandy Wong

June 9th 2021

OncLive sits down with Sandy Wong, MD; Neal Shore, MD; and Loretta Nastoupil, MD, to share the the insight on data in multiple myeloma, prostate cancer, and non-Hodgkin lymphoma at the 2021 ASCO Annual Meeting.

Dr. Markowski on the Safety and Efficacy of VERU-111 in mCRPC

June 8th 2021

Mark Christopher Markowski, MD, PhD, discusses the safety and efficacy of VERU-111 in patients with metastatic castration-resistant prostate cancer.

Dr. Dreicer on the Goals of the Phase 3 VERACITY Trial With VERU-111 in mCRPC

June 8th 2021

Robert Dreicer, MD, discusses the goals of the phase 3 VERACITY trial with VERU-111 in patients with metastatic castration-resistant prostate cancer.

TAK-700 Plus ADT Significantly Improves PFS and PSA Responses in mHSPC, But Not OS

June 8th 2021

The addition of TAK-700 to androgen-deprivation therapy improved median progression-free survival and prostate-specific antigen responses, but did not significantly improve overall survival vs ADT and bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer.

Men With African Ancestry Less Likely to Receive Early Genomic Profiling in Prostate Cancer

June 8th 2021

Findings of a study examining comprehensive genomic profiling shed more light on disparities in prostate cancer care.

Fracture Risk Reduced With BPAs During Radium-223/Enzalutamide Treatment in mCRPC

June 8th 2021

Bone-protecting agents utilized during treatment with radium-223 plus enzalutamide reduced the risk for fractures in men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer.

Antitumor Activity Demonstrated With Novel PSMA-Targeted Agent HPN424 in mCRPC

June 4th 2021

The tri-specific half-life extended prostate-specific membrane antigen-targeting T cell engager HPN424 demonstrated antitumor activity and was well tolerated in patients with metastatic castration-resistant prostate cancer.

Extended Treatment With Darolutamide Well Tolerated, Prolongs Survival in Nonmetastatic CRPC

June 4th 2021

Darolutamide remained well tolerated with a highly favorable safety profile when combined with androgen deprivation therapy in the treatment of patients with nonmetastatic castration-resistant prostate cancer.

177Lu-PSMA-617 Plus Standard of Care Improves OS in mCRPC

June 3rd 2021

177Lu-PSMA-617, a targeted radioligand therapy, plus standard of care induced approximately a 40% reduction in the risk of death vs SOC alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Dr. Zhu on Treatment Strategies for Node-Positive Prostate Cancer

June 2nd 2021

Jason Zhu, MD, discusses treatment strategies for patients with node-positive prostate cancer.

Dr. Burgess on Improving Biomarkers for PARP Inhibitors in Prostate Cancer

June 2nd 2021

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.

Johnson Shines a Light on Racial Disparities in Breast Cancer, Prostate Cancer, and Beyond

June 2nd 2021

Anita Johnson, MD, FACS, discusses existing disparities in cancer, studies that have helped to shed further light on the issue, and ongoing efforts being made to improve outcomes in all patients.

Cabozantinib Plus Atezolizumab Shows Promise in High-Risk Castration-Resistant Prostate Cancer

May 31st 2021

The combination of cabozantinib plus atezolizumab was found to elicit encouraging response rates, disease control, and acceptable safety in patients with metastatic castration-resistant prostate cancer who had previously received enzalutamide and/or abiraterone acetate.